Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Expenses (2016 - 2026)

Heron Therapeutics filings provide 15 years of Operating Expenses readings, the most recent being $28.8 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 5.66% to $28.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $117.6 million, a 3.71% increase, with the full-year FY2025 number at $116.1 million, down 0.91% from a year prior.
  • Operating Expenses hit $28.8 million in Q1 2026 for Heron Therapeutics, down from $29.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $86.4 million in Q1 2022 to a low of $26.4 million in Q4 2024.
  • Median Operating Expenses over the past 5 years was $32.0 million (2024), compared with a mean of $40.6 million.
  • The widest YoY moves for Operating Expenses: up 19.75% in 2022, down 49.11% in 2022.
  • Heron Therapeutics' Operating Expenses stood at $37.8 million in 2022, then fell by 8.44% to $34.6 million in 2023, then fell by 23.69% to $26.4 million in 2024, then grew by 11.57% to $29.4 million in 2025, then decreased by 2.01% to $28.8 million in 2026.
  • The last three reported values for Operating Expenses were $28.8 million (Q1 2026), $29.4 million (Q4 2025), and $30.4 million (Q3 2025) per Business Quant data.